Our study identifies an oncogenic role of ciRs-6 and suggests its usefulness as a novel biomarker for bladder cancer diagnosis and prognosis and as a therapeutic target for bladder cancer.
ciRs-6 upregulates March1 to suppress bladder cancer growth by sponging miR-653.